Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 257 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ February 10, 2019 FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... August 18, 2023 5 Tips for Managing Financial Stress During Cancer April 19, 2022 An unexpected find: clues about the genetics of children’s cancer found... April 6, 2021 Load more HOT NEWS Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients
